Sutent Eiropas Savienība - slovāku - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Klertis 50 mg Slovākija - slovāku - ŠÚKL (Štátny ústav pre kontrolu liečiv)

klertis 50 mg

egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica

Klertis 25 mg Slovākija - slovāku - ŠÚKL (Štátny ústav pre kontrolu liečiv)

klertis 25 mg

egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica

Klertis 12,5 mg Slovākija - slovāku - ŠÚKL (Štátny ústav pre kontrolu liečiv)

klertis 12,5 mg

egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica

Inlyta Eiropas Savienība - slovāku - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - karcinóm, obličková bunka - protein kinase inhibítory - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.